E-Star BioTech

Executive Summary

E-Star BioTech is a private, Phase 2 biotechnology company headquartered in San Diego, pioneering a novel therapeutic approach for hypertension. Its lead candidate, MANP, is a designer peptide that activates guanylyl cyclase A (GC-A), a key receptor in blood pressure regulation. The ongoing BOLD-HTN Study is a Phase 2 clinical trial evaluating MANP in patients with uncontrolled blood pressure, building on a growing body of evidence that GC-A activation can lower blood pressure through vasodilation and natriuresis. If successful, MANP could offer a first-in-class treatment option for the large unmet need in hypertension, particularly for patients who are resistant to current therapies. The company is privately held and has not disclosed total funding or valuation, but its focus on a novel mechanism and early positive data suggest it is a promising player in the cardiovascular space. With Phase 2 enrollment ongoing, E-Star BioTech is positioned to generate pivotal data within the next year, which could attract strategic partnerships or additional financing to advance the program through later-stage development.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 BOLD-HTN Study Top-Line Data60% success
• H2 2026Potential Strategic Partnership or Licensing Deal40% success
• Q3 2026Initiation of Phase 2b/3 Dose-Ranging Trial50% success